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reduction of the HDRS score with 3.9. However, lithium as a 
covariant was responsible for the outcome difference, not 
the group of stimulation. No adverse events were reported. 
Comparing the differences of both groups in the pre- and 
post-study performance in a trail-making test, a group effect 
for the UHF group that was not influenced by the lithium in-
take was observed.  Conclusion: A 30-Hz left prefrontal rTMS 
in severely depressed patients was safe and no adverse 
events occurred. Due to a strong effect of lithium as a covari-
ate, we could not demonstrate favorable antidepressant ef-
fects of the UHF stimulation compared to sham. However, 
we found an improvement of processing speed performance 
in the UHF group, which covaried with improvement of psy-
chomotor retardation.  Copyright © 2012 S. Karger AG, Basel
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 Abstract
 Background and Aim: Repetitive transcranial magnetic 
stimulation (rTMS) is supposed to be not as effective in se-
vere depression as it is in medium depression. We evaluated 
the treatment response to an ultra-high-frequency (UHF; 30 
Hz) approach, which was used to maximize the rTMS efficacy 
in severely ill patients.  Methods: 43 severely depressed pa-
tients were included in the randomized, double-blind study 
and received either rTMS with 30 Hz over the left dorsolat-
eral prefrontal cortex or sham condition for 3 weeks as an 
add-on therapy to stable antidepressant medication. Hamil-
ton Depression Rating Scale (HDRS) and cognitive perfor-
mance were evaluated before and after the intervention.  Re-
sults: In the active UHF group, the HRDS score was reduced 
by about 7.2, whereas the sham condition showed a smaller 
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 Repetitive transcranial magnetic stimulation (rTMS) 
has transformed from a neurological research tool into a 
highly promising treatment alternative in psychiatry. Es-
pecially in the therapy of major depressive disorder, the 
noninvasive rTMS has reached considerable attention 
with milestones like the first clinical trial  [1] , the approv-
al by the US Food and Drug Administration  [2] or the 
publication of the to date largest multisite study  [3] with-
in the last two decades. Alternatives to antidepressants 
are urgently needed, as about one third of patients will 
not remit with their first antidepressant challenge and 
15% of the patients with depression are not helped at all 
by antidepressant medication. Existing data regarding 
antidepressant efficacy of rTMS are somewhat inclusive, 
meaning that there are many reports that were able to 
demonstrate antidepressant effects  [3–7] , but equally re-
ports that could not show superiority to sham treatment 
or arguable clinically relevant effects  [8–12] . However, 
the majority of meta-analyses concludes that rTMS is su-
perior to sham in the treatment of depression  [13–17] . 
Most studies agree that the differential influence of in-
tensity, duration, and frequency of rTMS on antidepres-
sive efficacy has not been fully explored so far. rTMS is 
supposed to be more successful in patients whose degree 
of depression is rather mild to medium than severe. Un-
fortunately, in severely depressed patients, treatment re-
sistance is frequent and new options are most valuable 
especially for this population.
 We evaluated the treatment response to an ultra-high-
frequency (UHF; 30 Hz) approach over the left dorsolat-
eral prefrontal cortex, which was used to maximize the 
rTMS efficacy in severely ill patients. A 30-Hz stimula-
tion frequency is about 50% higher than the usual high-
frequency stimulation, but considering the large number 
of subjects and patients who have undergone rTMS stud-
ies and the small number of seizures, the risk of rTMS to 
induce seizures is certainly very low  [18, 19] . Fifty hertz 
was already used in patients with Parkinson’s disease; 30 
Hz is to our knowledge the highest frequency used to an-
alyze antidepressant characteristics in patients with de-
pression. An animal study with a model of depression 
that compared 20- and 30-Hz stimulation already sug-
gested that the effectiveness of rTMS may be augmented 
by increasing the frequency of rTMS impulses  [20] .
 In order to create ‘real world’ conditions, we used a 
naturalistic augmentation or add-on study, with patients 
continuing the antidepressant medication they already 
took before the study, but that had not led to a response.
 Methods
 Patients
 The present study has been carried out in accordance with the 
Code of Ethics of the World Medical Association (Declaration of 
Helsinki) and written informed consent was obtained from all 
participants before inclusion in the study. There were two cohorts 
(n = 26 and n = 17) with a total sample of 43 depressed subjects 
(16 males and 27 females), who were recruited between 2007 and 
2009 from the Department of Biological Psychiatry and Neurosci-
ence, Evangelical Clinics Gelsenkirchen, Germany. Inclusion cri-
teria were beneath the present primary diagnosis of at least a mod-
erate depressive episode with a minimum of 20 points on the 
HDRS without psychotic features (DSM-IV: 296.52, 296.53, 
296.32, 296.33, 296.22, or 296.23), age from 18 to 75 years and both 
a certain stability of the course (no relevant change in the week 
before the start of the study) and stability of antidepressant med-
ication (intake of either venlafaxine or mirtazapine over at least 3 
weeks). Exclusion criteria were a history of seizures, moderate to 
severe head traumas or brain surgery, current other psychiatric 
disorders, current severe neurological or medical diseases or the 
implementation of a pacemaker. Before inclusion, internal and 
neurological examinations and additionally laboratory and EEG 
were performed.
 In order to facilitate a clinical realistic study, all patients re-
ceived an antidepressant pharmacological standard treatment 
with either venlafaxine or mirtazapine and additional standard 
inpatient treatment as usual. Inclusion was possible after at least 
3 weeks of stable intake of one of these antidepressants. The al-
lowed concomitant medication was lithium, when already estab-
lished at least 4 weeks before inclusion, lorazepam up to 1.5 mg/
day and antipsychotics. Anticonvulsive mood stabilizers were not 
allowed throughout the study.
 Baseline stability is an important issue regarding minimizing 
bias through placebo response and naturalistic course; in order to 
exclude patients who got better without intervention, it was neces-
sary that the HDRS score did not improve over 20% between 1 
week before stimulation and at the day of the first scheduled stim-
ulation. If an improvement over 20% occurs and the inclusion 
criteria are still fulfilled, the study intervention is postponed an-
other week. Then baseline stability is checked again, and if there 
is still an improvement over 20%, the patient is excluded from the 
study.
 Outcome Measures
 The primary endpoint of the study was a clinician-rated mea-
sure of depressive symptoms with the HDRS (21-item version). 
Weekly rating was performed by the psychiatrist on ward, who 
had daily contact with the patient, but was not involved in the 
study at all and was not aware of the patient’s group (active stim-
ulation or sham), thus resulting in a double-blind condition.
 Secondary outcome parameters were the self-reported mea-
sure of depressive symptoms using Beck’s Depression Inventory 
(BDI) and performance using three cognitive tests, namely the 
Zahlen-Verbindungs-Test (ZVT), a cognitive test that included a 
trail-making test challenging processing speed  [21] , the Syndrom-
Kurztest (SKT), a brief neuropsychological test battery for the as-
sessment of potential deficits in memory and attention  [22] , and 
the Mehrfachwahl-Wortschatz-Test Version B, a multiple-choice 
verbal intelligence test estimating the premorbid intelligence lev-
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el. Another parameter was patient satisfaction with the rTMS 
treatment measured with a visual analogue scale after the com-
pletion of the study.
 Evaluation of all outcome parameters took place before the 
rTMS treatment and after completion of 3 weeks of stimulation. 
Another outcome parameter was if the patient could be consid-
ered as ‘responder’, which is defined as a reduction of at least 50% 
in HDRS score, or as ‘remitter’, which is defined as an HDRS
score  ! 8.
 rTMS Treatment
 rTMS was administered using a MagPro stimulator (Dantec, 
Denmark) with a figure-of-eight coil with an outer diameter of 97 
mm. Prior to the initial rTMS session, the resting motor threshold 
was determined as the lowest intensity that could induce an invol-
untary movement of the abductor pollicis brevis muscle in at least 
3 out of 6 times. Stimulation was applied at 110% of the motor 
threshold. Coil positioning was determined by the 10–20 EEG 
system, such that F3 corresponds to the left dorsolateral prefron-
tal cortex  [23] . We chose two different, alternated randomized 
stimulus conditions. Stimulation was performed for 3 weeks on 
each workday (total of 15 sessions).
 Left-side UHF (30 Hz) stimulation was applied in 20 trains of 
3-second duration with 57-second intertrain intervals, resulting 
in 1,800 pulses per session. This condition was regarded as the 
active treatment with hypothesized antidepressant efficacy.
 Left-side low-frequency (LF; 1 Hz) stimulation was applied in 
11 trains of 90-second duration with 30-second intertrain inter-
vals, totalling 990 pulses per session. That condition was regarded 
as the not active, sham treatment.
 Statistical Analysis
 All statistics were performed using STATA  (version 11; Stata-
Corp, Tex., USA) at a significance level of 0.05, except for the three 
cognitive tests, where we corrected for multiple testing with Bon-
ferroni correction with a significance level of 0.05/3 = 0.017. Base-
line differences between the two groups were analyzed with the 
two-tailed paired t tests or, if appropriate, with Pearson’s   2  test. 
Comparisons of the outcome parameters (HDRS, BDI, ZVT, SKT, 
Mehrfachwahl-Wortschatz-Test Version B) before and after the 
rTMS treatment were analyzed with two-tailed paired t tests. 
Comparisons between the two stimulation groups were carried 
out with one-way ANOVA, including possible covariates.
 Results
 Characteristics of the Study Population
 We could include altogether 43 subjects in two co-
horts. Unfortunately, the second cohort (n = 17) lacks in-
formation about the intake of lithium, benzodiazepines 
and antipsychotics during the study. There were no sig-
nificant baseline differences in the two cohorts. Twenty-
two subjects were randomized for the UHF group and 21 
subjects for the LF group. No patient was excluded due to 
insufficient baseline stability. Demographic and baseline 
clinical information are shown in  table 1 .
 In the UHF group, 68.2% were female and the average 
age was 56.9 years (SD: 10.2). The baseline HDRS score 
was 30.4 (SD: 4.8) and the baseline self-rated BDI score 
was 32.0 (SD: 11.9). In the LF group, 57.1% were female 
and the mean age was 54.1 (SD: 7.8). The HDRS mean 
score before the treatment was 28.2 (3.9) and the BDI 
mean score was 29.0 (SD: 9.6). The stimulus intensity and 
the duration of illness did not differ in the two groups 
[stimulus intensity: UHF, 43.4% (SD: 2.9) and LF, 43.2% 
(SD: 2.0); duration of illness: UHF, 6.9 years (SD: 3.4) and 
LF, 6.4 years (SD: 6.0)]. However, 33.8% of the patients in 
the active UHF group were taking lithium during the 
study, but no patient in the sham LF group did (p = 0.049) 
and benzodiazepine intake was significantly more often 
observed in the active group [UHF: 87.5% and LF: 50.0% 
(p = 0.04)]. Antipsychotics were taken during the study 
by 81.3% of patients in the UHF group and by 50.0% of 
the subjects in the LF group (p = 0.09).
 Safety
 Thirty-hertz UHF was well tolerated by the partici-
pants. All patients completed the study and no seizure 
occurred. No adverse events were reported by the pa-
tients. In the patient satisfaction of the treatment mea-
sured with a visual analogue scale, we found no differ-
ence between the two groups [F(1, 41) = 0.03, p = 0.86; 
data not shown].
 Clinical Outcome Parameters
 The clinical outcome parameters are presented in  ta-
ble 2 . The primary endpoint of the study was the differ-
ence between the baseline HDRS score and the final 
 Table 1.  Demographic data of both groups
 UHF (active)  LF (sham)  p 
 Number 22  21 
 Male/female, % 31.8/68.2  42.9/57.1  0.45 
 Age, years 56.9810.2  54.187.8   0.31 
 HDRS score before rTMS 30.484.8  28.283.9  0.12 
 BDI score before rTMS 32.0811.9  29.089.6  0.37 
 Stimulus intensity, % 43.482.9  43.282.0  0.87 
 Duration of illness, years 6.983.4 6.486.0  0.75 
 Lithium, % 31.3 (n = 16) 0.0 (n = 10)  0.05 
 Antipsychotics, %  81.25 (n = 16)  50.0 (n = 10)  0.09 
 Benzodiazepines, %   87.50 (n = 16)  50.0 (n = 10)  0.04 
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HDRS score after the study. The final HDRS score after 
3 weeks of add-on rTMS was 23.1 (SD: 5.7; range: 12–34) 
in the active group and 24.3 (SD: 5.7; range: 11–35) in the 
sham group. Both groups showed an improvement of 
symptoms measured by the HDRS; the active, UHF group 
showed an average reduction of the HDRS score of 7.2 
(SD: 4.2; range: 2–17, p  ! 0.001), whereas the sham condi-
tion, LF group showed a significantly smaller reduction 
of the HDRS score of 3.9 (SD: 3.8; range: 0–13, p  ! 0.001) 
[F(1, 41) = 7.5, p = 0.009]. However, lithium as a covariant, 
which was unequally distributed between the two groups 
despite randomization, was responsible for the difference 
in outcome [F(1, 23) = 13.8, p = 0.001], but not the group 
of stimulation [F(1, 23) = 0.3, p = 0.58]. Other covariates 
such as sex, age, antipsychotic or benzodiazepine intake 
had no significant influence on the results.
 Due to the strong lithium influence, the HDRS score 
between the patients who took lithium [n = 5; HDRS 
score difference: 12.6 (4.7)] and those who did not [n = 11; 
HDRS score difference: 6 (2.3)] within the UHF group 
was compared and a statistically significant difference 
was found [F(1, 15) = 14.85, p = 0.0018].
 In a subgroup analysis, patients were divided into two 
groups: very severely depressed with an HDRS score  6 30 
[n = 21, HDRS score: 33.0 (SD: 2.5)] and severely de-
pressed patients with an HDRS score  ! 30 [n = 22, HDSR 
score: 25.9 (SD: 2.8)]. In both subgroups, we found no su-
periority of UHF compared to LF stimulation [severely 
depressed patients: F(1, 20) = 2.55, p = 0.13 and very se-
verely depressed patients: F(1, 10) = 0.2, p = 0.66)], when 
considering the lithium covariate.
 The difference between baseline and final BDI score 
showed an amelioration of self-perceived depressive 
symptoms over the study in both groups [UHF: 6.3 (SD: 
6.3), p  ! 0.001; LF: 5.3 (SD: 7.1), p = 0.003]. However, there 
were no differences between the active and the sham 
group [F(1, 41) = 0.26, p = 0.62]. There were no patients in 
both groups who reached the state of remission after the 
study. Four patients reached the criteria defined as re-
sponse; all were in the UHF group, and 3 of them were 
taking lithium.
 Cognitive Parameters
 The cognitive parameters are summarized in  table 3 . 
While the sham (LF) group showed no difference in the 
pre- and post-study performance in the ZVT (2.1; SD: 
27.4, p = 0.21), the active group showed a significant im-
provement of the cognitive performance in this test (20.6; 
SD: 16.7, p  ! 0.0001). Comparing the differences of both 
groups, we found a clear-cut group effect for the UHF 
group [F (1, 41) = 7.2, p = 0.010] that was not influenced 
in a significant manner by the lithium intake and was 
significant even after correction for multiple testing.
 In the SKT, we found an improvement of test perfor-
mance in the post-study test compared to the baseline test 
before the stimulation in both groups [UHF: 2.5, SD: 2.3, 
p  ! 0.001; LF: 1.3 (SD: 1.6), p = 0.008], but no significant 
group difference [F(1, 41) = 3.6, p = 0.06].
 Similar to the SKT, in the Mehrfachwahl-Wortschatz-
Test Version B, we found an improvement over time in 
both groups [UHF: 3.9 (SD: 3.8), p  ! 0.001; LF: 2.8 (SD: 
 Table 2.  Clinical outcome data of both groups
 UHF (active)  LF (sham)  p  
 Final HDRS score  23.185.7   24.385.7  0.48 
 HDRS score difference 7.284.2  3.983.8   0.01a 
 Without lithium 5.782.3  3.983.8  0.11 
 HDRS score reduction, %  23.9  13.8  – 
 Without lithium  18.8  13.8  – 
 Final BDI score  32.0811.9   29.089.7  0.60 
 BDI score difference 6.386.3 5.387.1  0.62 
 Remission  0 0  – 
 Response 4a (18.2%) 0  0.32 
 Data are presented as means with standard deviation.
 a 3 out of 4 patients with response in the active treatment group 
were taking lithium during the study. 
 
 
 Table 3.  Outcome of the cognitive tests in both groups
 UHF (active)  LF (sham)  p 
 ZVT 
 Baseline  166864.5  139.1847.8  n.s. 
 Final  145.4860.4  131.7848.8  n.s. 
 Difference 20.6816.7 2.1827.4  0.010 
 SKT 
 Baseline 7.685.7 4.983.3  – 
 Final 4.985.5 3.883.8  – 




 Baseline 31.482.1 34.682.1  – 
 Final 35.382.6 37.482.7  – 
 Difference 3.983.8 2.884.7  0.385 
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4.7), p = 0.015], but no group difference [F (1, 41) = 0.77,
p = 0.39].
 As we could show a stable group difference in the ZVT, 
a trail-making test, but not in the other cognitive tests, we 
assumed that the unique component of the ZVT is pro-
cessing speed. We hypothesized, that rTMS might lead to 
an amelioration of psychomotor retardation measured by 
the change of item 8 in the HDRS. Thus we found a sig-
nificant influence of the covariate ‘psychomotor retarda-
tion’ on the performance in the ZVT [F (2, 24) = 4.54,
p = 0.044]. However, the effect was not strong enough to 
produce a group difference of the improvement of psy-
chomotor retardation measured by the change of item 8 
of the HDRS [F (1, 31) = 0.04, p = 0.84].
 Discussion
 In this randomized, double-blind trial, the patients re-
ceived 3 weeks of rTMS treatment additionally to a con-
current stable antidepressant medication that alone did 
not lead to a significant antidepressant response. UHF 
stimulation at the left dorsolateral prefrontal cortex was 
considered as the active treatment, whereas left LF stimu-
lation was considered as the nonactive, sham treatment.
 In this rTMS study, we present two innovations: we 
recruited a sample of the most severely depressed patients 
with a baseline HDRS score (21-item version) of about 30 
in the active treatment group. In the literature, an HDRS 
score of at least 25 is already considered as severely de-
pressed  [24, 25] . To our knowledge, no published ran-
domized rTMS study with depressed patients had a high-
er HDRS baseline score. Because there are doubts about 
the potency of rTMS in such a severely depressed sample 
 [26, 27] , we wanted to provide maximum power of the 
rTMS method by raising the stimulus frequency up to 30 
Hz, which we consider as UHF. In an animal model of 
depression, the forced swim test, different frequencies 
were tested for their antidepressant effects. All tested fre-
quencies (1–25 Hz) showed antidepressant efficacy com-
parable with the potency of imipramine. The findings 
suggest that the antidepressant effect of the higher fre-
quencies is likely to be sustained  [28] . To our knowledge, 
in the already published, randomized studies, frequen-
cies up to 20 Hz were used, thus our approach is 50% 
higher than the already quite established paradigms. 
Safety data already exist for the 50-Hz stimulation ap-
proach from a study with patients suffering from Parkin-
son’s disease  [29] .
 In both groups, the patients showed an improvement 
over the 3 weeks of the study phase, but the difference 
between UHF and LF was based on the lithium effect or 
on the combination of lithium and rTMS, but not on 
a superior stimulation frequency. Unfortunately, there 
were 31.3% of patients in the UHF groups who were tak-
ing lithium, and no patient in the LF group. Especially the 
lithium patients showed a good response that resulted in 
a detectable group effect. Improvement in terms of HDRS 
score reduction in both groups was in the range of previ-
ous studies; however, only 18.2% in the UHF group 
showed a response to treatment – and only 4.6% without 
lithium intake. This is considerably less than compared 
to other studies with not so severely depressed patients
 [3, 30] .
 In spite of randomization, unequal distribution of im-
portant variants is a not uncommon problem in small 
sample studies. However, there are several other reasons 
why identification of a group difference failed. We de-
signed this study as an add-on study in order to provide 
more naturalistic data, but in add-on trials, it is known 
that the sham response is higher than in studies without 
concomitant antidepressant medication and sham re-
sponse is known to be considerably large  [31] . In fact, with 
a similar add-on design, a multicenter study with 127 pa-
tients investigating antidepressant efficacy failed to dem-
onstrate beneficial results  [32] . However, other add-on 
studies with patients who were also severely depressed 
could demonstrate superiority of active treatment over 
sham treatment, with 5 and 10 Hz, respectively  [6, 33, 34] .
 Secondly, the sham group showed HDRS and BDI 
score improvement over the study time, which could be a 
placebo response or the natural course of patients, whose 
depressive symptoms were severe but who were not con-
sidered treatment-resistant as per definition  [35] . The 
sham group got left LF stimulation, thus making it very 
difficult for the participants to figure out, which treat-
ment they received. That is why we can assume that par-
ticipants showed full placebo response of this kind of sug-
gestive method, which might make it even more difficult 
to detect possible existing group differences. Some au-
thors share the opinion that nonpharmacological inter-
ventions might produce a greater placebo response than 
pharmacological ones  [36] , but others state that placebo 
rates decrease with severity of depression  [37, 38] . Fur-
thermore, it cannot be ruled out that our sham condition 
also demonstrated some antidepressant effect, as LF 
rTMS also has an effect in the regional cerebral flow  [39] . 
However, choosing a sham condition is a trade-off be-
tween effective blinding and truly inactive ‘stimulation’ 
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 [40] . At least from a clinical point of view, our sham ap-
proach did not reveal any relevant effects. No patient 
from the sham group worsened and the response in the 
sham group with a mean score reduction of 3.9 in the 
HRDS was within the reported limits of other groups  [3, 
33] .
 Another possible explanation for the negative finding 
is that the study duration of 3 weeks was simply not long 
enough to develop a group difference without the lithium 
covariant. Longer treatment duration seems to be better 
in terms of antidepressant efficacy  [41, 42] and two other 
studies with very severely depressed patients who had a 
baseline HDRS score of about 30 and a positive finding 
treated the patients between 4 and 6 weeks  [2, 33] . That is 
supported by our finding that the cognitive performance 
in one test (ZVT, trail-making test character) improved 
considerably in the active treatment group independent 
from an antidepressant effect of rTMS, while it did not in 
the sham group. In this test, processing speed was in-
volved, which is known to be considerably disturbed in 
major depression  [43] , but was no major compound in the 
two other psychological tests, in which no group differ-
ence occurred. Improved performance in trial-making 
tests could point towards an amelioration of frontal lobe 
deficits, which might be an effect of the UHF stimulation. 
rTMS has already shown to improve cognitive function 
in Alzheimer’s disease  [44] . Additionally, rTMS might 
specifically target psychomotor retardation as a core 
symptom of depression, thus resulting in fast and better 
performance in speed processing tasks, which are valid 
measurements for psychomotor retardation  [45, 46] . Two 
studies already reported that despite a lack of efficacy in 
terms of HDRS score reduction, high-frequency rTMS (10 
and 20 Hz, respectively) significantly decreased scores on 
the psychomotor retardation scales  [10, 47] , whereas an-
other study did not find such associations. In our study, 
we found a significant influence of the covariate ‘psycho-
motor retardation’ (quantified by HRDS item 8) on the 
performance in the trail-making test, thus pointing to-
wards the fact that reduction in psychomotor retardation 
might be an early step of antidepressant response, similar 
to some antidepressants.
 Another finding worth mentioning is that in the active 
UHF group, the patients who took lithium had a higher 
HDRS score reduction than those patients who did not 
take lithium. This was not necessarily expected, because 
patients taking lithium were only included in the study, 
if lithium had already been given for at least 4 weeks be-
fore the start of the stimulation. Although very prelimi-
nary, our finding might suggest that lithium is a favorable 
concomitant medication in rTMS and that the combina-
tion might facilitate more effects than lithium or rTMS 
alone.
 Limitations of the study are the unequal distribution 
of lithium intake, which in combination with the modest 
sample size unfortunately limits the informative value. 
Another problem of the study is the additional intake of 
benzodiazepines and antipsychotics, which was either 
unequally distributed or the information about the intake 
was missing. In studies investigating antidepressant ef-
fects, the use of these two groups of drugs is problematic, 
because both are known to be able to improve sleep and 
anxiety, without having clear-cut antidepressant effects, 
perhaps with quetiapine as an exception. Therefore, anti-
psychotics might reduce the HDRS score with its three 
sleep-related items, without unique antidepressant ef-
fects.
 In summary, 30-Hz left prefrontal rTMS in severely 
depressed patients was safe and no adverse events oc-
curred. Due to unequal distribution of lithium, we were 
not able to demonstrate an antidepressant group differ-
ence compared to sham. However, we found an improve-
ment of processing speed performance in the stimulation 
group, which covaried with the improvement of psycho-
motor retardation. Treating severely depressed patients 
with rTMS could not be discarded based on our data, es-
pecially when bearing in mind that even a mild or modest 
amelioration, which rTMS could deliver in combination 
with antidepressants, might have a relevant clinical effect 
in terms of suicidal prevention or regaining the ability for 
psychotherapeutic work.
 Future clinical research in rTMS for affective disor-
ders has to deal with many aspects. Studying the impact 
of stimulation parameters (e.g. frequency or intensity) on 
the efficacy in order to optimize rTMS treatment  [48] is 
definitively one of them, and exploring favorable con-
comitant medication is another one. Alternative ap-
proaches that have been developed in the last few years, 
and might contain even more potential than the ‘conven-
tional’ rTMS method, are important and promising re-
search issues, too. Theta burst stimulation is one of them 
and involves the repetitive application of very short trains 
at high frequency (50 Hz) and very short intertrain inter-
vals  [49] , which is therefore still different from our ap-
proach. Preliminary data suggest that theta burst stimu-
lation is a safe method  [50] and may have antidepressant 
effects  [51, 52] .
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